Chinese study tracking myotonic dystrophy type 1 outcomes
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study follows people with myotonic dystrophy type 1 (DM1) over time to learn more about how the disease progresses. It collects health information and samples to help improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetic test confirming DM1 (a specific gene change).
- You can be any sex.
- You must be able to come for regular checkups and agree to give leftover blood and urine samples for research.
- You (or your guardian if you're a child) must sign a consent form agreeing to take part.
- You must allow the study team to use your regular medical data for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a long-term follow-up for people with myotonic dystrophy type 1. It aims to find better ways to measure how the disease progresses, which could help develop future treatments.
This study measures physical and lab “health markers” in people with myotonic dystrophy type 1 (DM1) to better understand how the disease changes over time. Some participants may also have a muscle biopsy to study tissue differences.
This study follows people with myotonic dystrophy (DM1 or DM2) for 2 years to learn more about the disease. You must already be in the DM-Scope registry and have certain medical records available.
This study builds a registry of people and families affected by myotonic dystrophy types 1 and 2. It helps researchers learn about the condition over time and may support future studies that could lead to better care.
This trial tests an experimental drug called ATX-01 for people with myotonic dystrophy type 1 (DM1), a condition that causes muscle weakness and stiffness. The study aims to see if ATX-01 can help reduce symptoms like muscle stiffness (myotonia) and improve daily function.
This study tests an experimental drug called PGN-EDODM1 for people with myotonic dystrophy type 1 (DM1). The goal is to see if it can help reduce symptoms like muscle stiffness (myotonia).
Hear when a new Myotonic Dystrophy 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.